| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999706 | Urologic Oncology: Seminars and Original Investigations | 2015 | 6 Pages |
Abstract
In a robust sample of patients who underwent RP in the United States, HACs were very uncommon and contributed approximately $1 million in additional expenditures. As the U.S. government continues to expand quality improvement programs and develop incentives to avoid complications, efforts to monitor unnecessary complications should continue as well.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Christopher M. M.D., M.P.H., Max M.D., James M. M.D., Benjamin A. M.D., M.P.H.,
